Literature DB >> 19484761

Alteration of enhancer of polycomb 1 at 10p11.2 is one of the genetic events leading to development of adult T-cell leukemia/lymphoma.

Shingo Nakahata1, Yusuke Saito, Makoto Hamasaki, Tomonori Hidaka, Yasuhito Arai, Tomohiko Taki, Masafumi Taniwaki, Kazuhiro Morishita.   

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is a malignant tumor caused by latent human T-lymphotropic virus 1 (HTLV-1) infection. We previously identified a common breakpoint cluster region at 10p11.2 in acute-type ATLL by spectral karyotyping. Single nucleotide polymorphism array comparative genomic hybridization analysis of the breakpoint region in three ATLL-related cell lines and four patient samples revealed that the chromosomal breakpoints are localized within the enhancer of polycomb 1 (EPC1) gene locus in an ATLL-derived cell line (SO4) and in one patient with acute-type ATLL. EPC1 is a human homologue of the E(Pc) enhancer of polycomb gene of Drosophila. Inappropriate expression of the polycomb group gene family has been linked to the loss of normal gene silencing pathways, which can contribute to the loss of cell identity and malignant transformation in many kinds of cancers. In the case of the SO4 cell line, which carried a der(10)t(2;10)(p23;p11.2) translocation, EPC1 was fused with the additional sex combs-like 2 (ASXL2) gene at 2p23.3 (EPC1/ASXL2). In the case with an acute-type ATLL, who carried a der(10)del(10)(p11.2)del(10)(q22q24) translocation, a putative truncated EPC1 gene (EPC1tr) was identified. Overexpression of EPC1/ASXL2 enhanced cell growth in T-leukemia cells, and a GAL4-EPC1/ASXL2 fusion protein showed high transcriptional activity. Although a GAL4-EPC1tr fusion protein did not activate transcription, overexpression of EPC1tr accelerated cell growth in leukemia cells, suggesting that the EPC1 structural abnormalities in the SO4 cell line and in the patient with acute-type ATLL may contribute to leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19484761     DOI: 10.1002/gcc.20681

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  Chromatin Regulation by the NuA4 Acetyltransferase Complex Is Mediated by Essential Interactions Between Enhancer of Polycomb (Epl1) and Esa1.

Authors:  Naomi E Searle; Ana Lilia Torres-Machorro; Lorraine Pillus
Journal:  Genetics       Date:  2017-01-20       Impact factor: 4.562

2.  RNA interference targeting enhancer of polycomb1 exerts anti-tumor effects in lung cancer.

Authors:  Chunli Che; Lijuan Zhang; Jianmin Huo; Yimei Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Enhancer of polycomb maintains germline activity and genome integrity in Drosophila testis.

Authors:  Lijuan Feng; Zhen Shi; Jing Xie; Binbin Ma; Xin Chen
Journal:  Cell Death Differ       Date:  2018-01-23       Impact factor: 15.828

Review 4.  Human Genetic Determinants of Viral Diseases.

Authors:  Adam D Kenney; James A Dowdle; Leonia Bozzacco; Temet M McMichael; Corine St Gelais; Amanda R Panfil; Yan Sun; Larry S Schlesinger; Matthew Z Anderson; Patrick L Green; Carolina B López; Brad R Rosenberg; Li Wu; Jacob S Yount
Journal:  Annu Rev Genet       Date:  2017-08-30       Impact factor: 16.830

Review 5.  Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2015-07-30       Impact factor: 12.944

6.  KAT5 silencing induces apoptosis of GBC-SD cells through p38MAPK-mediated upregulation of cleaved Casp9.

Authors:  Fei-Ling Feng; Yong Yu; Chen Liu; Bai-He Zhang; Qing-Bao Cheng; Bin Li; Wei-Feng Tan; Xiang-Ji Luo; Xiao-Qing Jiang
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

Review 7.  Critical genomic regulation mediated by Enhancer of Polycomb.

Authors:  Naomi E Searle; Lorraine Pillus
Journal:  Curr Genet       Date:  2017-09-07       Impact factor: 3.886

Review 8.  Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Authors:  Véronique Gelsi-Boyer; Mandy Brecqueville; Raynier Devillier; Anne Murati; Marie-Joelle Mozziconacci; Daniel Birnbaum
Journal:  J Hematol Oncol       Date:  2012-03-21       Impact factor: 17.388

Review 9.  Functional and cancer genomics of ASXL family members.

Authors:  M Katoh
Journal:  Br J Cancer       Date:  2013-06-04       Impact factor: 7.640

10.  Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells.

Authors:  X Huang; G J Spencer; J T Lynch; F Ciceri; T D D Somerville; T C P Somervaille
Journal:  Leukemia       Date:  2013-10-29       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.